142 related articles for article (PubMed ID: 21251824)
1. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
Jin M; Kleinberg A; Cooke A; Gokhale PC; Foreman K; Dong H; Siu KW; Bittner MA; Mulvihill KM; Yao Y; Landfair D; O'Connor M; Mak G; Pachter JA; Wild R; Rosenfeld-Franklin M; Ji Q; Mulvihill MJ
Bioorg Med Chem Lett; 2011 Feb; 21(4):1176-80. PubMed ID: 21251824
[TBL] [Abstract][Full Text] [Related]
2. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
3. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
Zimmermann K; Wittman MD; Saulnier MG; Velaparthi U; Sang X; Frennesson DB; Struzynski C; Seitz SP; He L; Carboni JM; Li A; Greer AF; Gottardis M; Attar RM; Yang Z; Balimane P; Discenza LN; Lee FY; Sinz M; Kim S; Vyas D
Bioorg Med Chem Lett; 2010 Mar; 20(5):1744-8. PubMed ID: 20153189
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
[TBL] [Abstract][Full Text] [Related]
5. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.
Mulvihill MJ; Cooke A; Rosenfeld-Franklin M; Buck E; Foreman K; Landfair D; O'Connor M; Pirritt C; Sun Y; Yao Y; Arnold LD; Gibson NW; Ji QS
Future Med Chem; 2009 Sep; 1(6):1153-71. PubMed ID: 21425998
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
Buchanan JL; Newcomb JR; Carney DP; Chaffee SC; Chai L; Cupples R; Epstein LF; Gallant P; Gu Y; Harmange JC; Hodge K; Houk BE; Huang X; Jona J; Joseph S; Jun HT; Kumar R; Li C; Lu J; Menges T; Morrison MJ; Novak PM; van der Plas S; Radinsky R; Rose PE; Sawant S; Sun JR; Surapaneni S; Turci SM; Xu K; Yanez E; Zhao H; Zhu X
Bioorg Med Chem Lett; 2011 Apr; 21(8):2394-9. PubMed ID: 21414779
[TBL] [Abstract][Full Text] [Related]
7. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
[TBL] [Abstract][Full Text] [Related]
8. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
[TBL] [Abstract][Full Text] [Related]
9. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
Martínez González S; Hernández AI; Varela C; Lorenzo M; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán MI; Alfonso P; García-Serelde B; Mateos G; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Blanco-Aparicio C; Pastor J
Bioorg Med Chem Lett; 2012 Aug; 22(16):5208-14. PubMed ID: 22819764
[TBL] [Abstract][Full Text] [Related]
10. Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.
Fairhurst RA; Marsilje TH; Stutz S; Boos A; Niklaus M; Chen B; Jiang S; Lu W; Furet P; McCarthy C; Stauffer F; Guagnano V; Vaupel A; Michellys PY; Schnell C; Jeay S
Bioorg Med Chem Lett; 2016 Apr; 26(8):2057-64. PubMed ID: 26951753
[TBL] [Abstract][Full Text] [Related]
11. Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases.
Wang GT; Mantei RA; Hubbard RD; Wilsbacher JL; Zhang Q; Tucker L; Hu X; Kovar P; Johnson EF; Osterling DJ; Bouska J; Wang J; Davidsen SK; Bell RL; Sheppard GS
Bioorg Med Chem Lett; 2010 Oct; 20(20):6067-71. PubMed ID: 20817523
[TBL] [Abstract][Full Text] [Related]
12. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.
Mortensen DS; Sapienza J; Lee BG; Perrin-Ninkovic SM; Harris R; Shevlin G; Parnes JS; Whitefield B; Hickman M; Khambatta G; Bisonette RR; Peng S; Gamez JC; Leisten J; Narla RK; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2013 Mar; 23(6):1588-91. PubMed ID: 23414803
[TBL] [Abstract][Full Text] [Related]
13. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
[TBL] [Abstract][Full Text] [Related]
14. Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.
Mayer SC; Banker AL; Boschelli F; Di L; Johnson M; Kenny CH; Krishnamurthy G; Kutterer K; Moy F; Petusky S; Ravi M; Tkach D; Tsou HR; Xu W
Bioorg Med Chem Lett; 2008 Jun; 18(12):3641-5. PubMed ID: 18501599
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
Wittman MD; Carboni JM; Yang Z; Lee FY; Antman M; Attar R; Balimane P; Chang C; Chen C; Discenza L; Frennesson D; Gottardis MM; Greer A; Hurlburt W; Johnson W; Langley DR; Li A; Li J; Liu P; Mastalerz H; Mathur A; Menard K; Patel K; Sack J; Sang X; Saulnier M; Smith D; Stefanski K; Trainor G; Velaparthi U; Zhang G; Zimmermann K; Vyas DM
J Med Chem; 2009 Dec; 52(23):7360-3. PubMed ID: 19778024
[TBL] [Abstract][Full Text] [Related]
16. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
Steiner L; Blum G; Friedmann Y; Levitzki A
Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
[TBL] [Abstract][Full Text] [Related]
18. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
[TBL] [Abstract][Full Text] [Related]
20. 2-Aminobenzimidazoles as potent Aurora kinase inhibitors.
Zhong M; Bui M; Shen W; Baskaran S; Allen DA; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris SO; Heumann SA; Hoch U; Ivy SN; Jacobs JW; Lam S; Lee H; McDowell RS; Oslob JD; Purkey HE; Romanowski MJ; Silverman JA; Tangonan BT; Taverna P; Yang W; Yoburn JC; Yu CH; Zimmerman KM; O'Brien T; Lew W
Bioorg Med Chem Lett; 2009 Sep; 19(17):5158-61. PubMed ID: 19646866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
